Literature DB >> 27184458

Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank.

Brian Dean1, David Copolov2, Elizabeth Scarr3.   

Abstract

The Melbourne Psychiatric Brain Bank came into existence 25years ago. This review focusses on lines of research that have used tissue from the Brain Bank over periods of time. Hence there is a discussion on the significance of changes in levels of serotonin 2A receptors in the cortex of patients with schizophrenia and the relevance of such changes with regards to the pathophysiology of the disorder. The extensive contribution made by studies using tissue from the Melbourne Psychiatric Brain Bank to understanding the role of muscarinic receptors in the pathophysiology and treatment of schizophrenia is summarised. Finally, findings using brain bank tissue and "omics" technologies are reviewed. In each case, findings using tissue from the Melbourne Psychiatric Brain Bank is placed in context with research carried out on human postmortem CNS in schizophrenia and with findings in other lines of research that can help explain the causes or consequences of changes in CNS molecular cytoarchitecture. This timely review of data from the Melbourne Psychiatric Brain Bank reinforces the challenges faced in trying to increase our understanding of the molecular pathophysiology of schizophrenia. Continuing to increase our understanding of the disorder is important as a precursor to identifying new drug targets that can be exploited to improve the treatment of a disorder where treatment resistance remains a significant problem (Millan et al., 2016).
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Muscarinic receptors; Postmortem; Schizophrenia; Serotonin 2A receptors

Mesh:

Year:  2016        PMID: 27184458     DOI: 10.1016/j.schres.2016.04.037

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  4 in total

1.  What a Clinician Should Know About the Neurobiology of Schizophrenia: A Historical Perspective to Current Understanding.

Authors:  Lynn E DeLisi
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 2.  Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.

Authors:  Kunal Maini; Janice W Hollier; Haley Gould; Victoria Bollich; John John LaForge; Elyse M Cornett; Amber N Edinoff; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-19

3.  An association study of the HSPA8 gene polymorphisms with schizophrenia in a Polish population.

Authors:  Malgorzata Kowalczyk; Aleksander Owczarek; Renata Suchanek-Raif; Krzysztof Kucia; Jan Kowalski
Journal:  Cell Stress Chaperones       Date:  2021-12-21       Impact factor: 3.667

Review 4.  Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.

Authors:  Kunal Maini; Haley Gould; Jessica Hicks; Fatima Iqbal; James Patterson; Amber N Edinoff; Elyse M Cornett; Adam M Kaye; Omar Viswanath; Ivan Urits; Alan D Kaye
Journal:  Neurol Int       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.